Imaging of infected total arthroplasty with Tc-99m-labeled antigranulocyte antibody Fab'fragments

Clin Nucl Med. 2004 Sep;29(9):548-51. doi: 10.1097/01.rlu.0000134981.56669.1e.

Abstract

Objective: The objective of this study was to evaluate the diagnostic accuracy of Tc-99m-labeled antigranulocyte antibody Fab' fragments in infected total arthroplasty.

Materials and methods: A total of 38 immunoscintigrams were evaluated retrospectively with 15 to 25 mCi Tc-99m-labeled antigranulocyte antibody-Fab' fragments. The final diagnosis was assessed by articular puncture or intraoperative sampling.

Results: In the total hip replacement group the authors found 10 true positives, 7 true negatives, 8 false positives, and 1 false negative; and in the total knee replacement group they found 4 true positives, 8 true negatives, and no false positives or false negatives. They also found a sensitivity of 93%, a specificity of 65%, and a positive predictive accuracy of 63%. There was a negative predictive accuracy of 94%.

Conclusion: The high negative predictive accuracy in the whole group suggests that the scan can be used to exclude infection in most cases. Negative results with a high clinical suspicion merits further investigation. A positive result will require further correlative imaging, especially for total knee replacement.

Publication types

  • Comparative Study
  • Evaluation Study
  • Validation Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal*
  • Antibodies, Monoclonal, Murine-Derived
  • Female
  • Hip Prosthesis / adverse effects*
  • Humans
  • Knee Prosthesis / adverse effects*
  • Male
  • Middle Aged
  • Prosthesis-Related Infections / diagnostic imaging*
  • Prosthesis-Related Infections / etiology*
  • Prosthesis-Related Infections / pathology
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Retrospective Studies
  • Sensitivity and Specificity

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Radiopharmaceuticals
  • Sulesomab